Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LQ036 Inhalation in Moderate-to-Severe Asthma
CTR20240350Phase 2Completed
- Sponsor
- Novamab Biopharmaceuticals
- Start
- Feb 2024
- Modality
- Nanobodies (VHH) → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of LQ036 in asthma, sponsored by Novamab Biopharmaceuticals. Started Feb 2024; status: completed.
02
Drugs
LQ036
03
Conditions
asthma
Beyond the preview
Go deeper on CTR20240350.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20240350.